Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative

European Journal of Cancer

Volumn 51, Issue 3, 2015, Pages 271-281

  Bogaerts, Jan ^a   Sydes, Matthew R ^b   Keat, Nicola ^c   McConnell, Andrea ^c   Benson, Al ^x   Ho, Alan ^d   Roth, Arnaud ^y   Fortpied, Catherine ^a   Eng, Cathy ^e   Peckitt, Clare ^f   Coens, Corneel ^a   Pettaway, Curtis ^e   Arnold, Dirk ^g   Hall, Emma ^h   Marshall, Ernie ⁱ   Sclafani, Francesco ^f   Hatcher, Helen ^j   Earl, Helena ^j   Ray Coquard, Isabelle ^k   Paul, James ^l   Blay, Jean Yves ^k   Whelan, Jeremy ^b   Panageas, Kathy ^d   Wheatley, Keith ^m   Harrington, Kevin ^h   Licitra, Lisa ⁿ   Billingham, Lucinda ^m   Hensley, Martee ^d   McCabe, Martin ^o   Patel, Poulam M ^z   Carvajal, Richard ^d,ab   Wilson, Richard ^p   Glynne Jones, Rob ^aa   McWilliams, Rob ^q   Leyvraz, Serge ^r   Rao, Sheela ^f   Nicholson, Steve ^s   Filiaci, Virginia ^t   Negrouk, Anastassia ^a   Lacombe, Denis ^a   Dupont, Elisabeth ^u   Pauporté, Iris ^v   Welch, John J ^u   Law, Kate ^c   Trimble, Ted ^u   Seymour, Matthew ^w   more..

^a EORTC DATA CENTER   (Belgium)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Royal Marsden   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁱ UNIVERSITY OF LIVERPOOL   (United Kingdom)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k Leon Berard Cancer Center   (France)

^l UNIVERSITY OF GLASGOW   (United Kingdom)

^m UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁿ NATIONAL CANCER INSTITUTE   (Italy)

^o UNIVERSITY OF MANCHESTER   (United Kingdom)

^p QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^q MAYO CLINIC   (United States)

^r LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^s Locum Consultant in Medical Oncology   (United Kingdom)

^t Gynecologic Oncology Group NRG Oncology   (United States)

^u NATIONAL CANCER INSTITUTE   (United States)

^v INSTITUT NATIONAL DU CANCER   (France)

^w The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^x NORTHWESTERN UNIVERSITY   (United States)

^y GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^z UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^aa MOUNT VERNON CANCER CENTRE   (United Kingdom)

^ab NewYork Presbyterian Hospital   (United States)

more..

Author keywords

Bayesian; Clinical trials; Frequentist; Methodology; Multi arm; Randomised controlled trials; Rare cancers

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CABOZANTINIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; TRAMETINIB; UPROSERTIB;

ANDROGEN DEPRIVATION THERAPY; ANUS CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; EWING SARCOMA; HIGH GRADE UNDIFFERENTIATED UTERINE SARCOMA; HUMAN; METASTASIS; METHODOLOGY; MULTICENTER STUDY (TOPIC); NEOPLASM; PENIS CARCINOMA; PENIS SQUAMOUS CELL CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; SALIVARY GLAND CANCER; SMALL BOWEL ADENOCARCINOMA; SMALL INTESTINE CARCINOMA; SQUAMOUS CELL CARCINOMA; STUDY DESIGN; UTERUS SARCOMA; UVEA MELANOMA; INTERNATIONAL COOPERATION; NEOPLASMS; ORGANIZATION AND MANAGEMENT; PROCEDURES; PUBLIC-PRIVATE PARTNERSHIP; RARE DISEASES;

HUMANS; INTERNATIONAL COOPERATION; NEOPLASMS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; RESEARCH DESIGN;

EID: 84922655364     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.10.027     Document Type: Review

References (41)

1. G. Gatta, J.M. van der Zwan, and P.G. Casali Rare cancers are not so rare: the rare cancer burden in Europe Eur J Cancer 47 17 2011 2493 2511
2. National Cancer Institute. Surveillance, epidemiology, and end results (SEER) program stat fact sheets: anal cancer, < http://seer.cancer.gov/statfacts/html/anus.html > [accessed 03.09.14].
3. Cancer Research UK. Anal cancer incidence statistics. Cancer Research UK, < http://www.cancerresearchuk.org/cancer-info/cancerstats/types/anal-cancer/Incidence/ >; 2014 [accessed 03.09.14].
4. R. Simon, R.E. Wittes, and S.S. Ellenberg Randomized phase II clinical trials Cancer Treat Rep 69 12 1985 1375 1381
5. H.C.J. Jaspers, B.M. Verbist, and R. Schoffelen Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options J Clin Oncol 29 16 2011 e473 e476
6. L. Locati, M. Mela, and P. Quattrone Anti-androgen therapy in recurrent and/or metastatic salivary glands carcinoma (RSGC) Ann Oncol 14 Supp 4 (AOIM meeting) 2003 iv16 iv29
7. L.D. Locati, F. Perrone, and M. Losa Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs) Oral Oncol 45 11 2009 986 990
8. R.W. van der Hulst, J.H. van Krieken, and T.H. van der Kwast Partial remission of parotid gland carcinoma after goserelin Lancet 344 8925 1994 817
9. B.L. Harlow, N.S. Weiss, and S. Lofton The epidemiology of sarcomas of the uterus J Natl Cancer Inst 76 3 1986 399 402
10. R. Koivisto-Korander, J.I. Martinsen, E. Weiderpass, A. Leminen, and E. Pukkala Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: results from NORDCAN and NOCCA databases Maturitas 72 1 2012 56 60
11. M.L. Hensley, J.K. Wathen, and R.G. Maki Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005) Cancer 119 8 2013 1555 1561
12. O. Zivanovic, M.M. Leitao, and A. Iasonos Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and American joint committee on cancer staging systems J Clin Oncol 27 12 2009 2066 2072
13. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15 Arch Ophthalmol 119 5 2001 670 676
14. D. Strickland, and J.A. Lee Melanomas of eye: stability of rates Am J Epidemiol 113 6 1981 700 702
15. E.S. Gragoudas, K.M. Egan, and J.M. Seddon Survival of patients with metastases from uveal melanoma Ophthalmology 98 3 1991 383 389 [discussion 90]
16. P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation New Engl J Med 364 26 2011 2507 2516
17. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma New Engl J Med 363 8 2010 711 723
18. C. Robert, L. Thomas, and I. Bondarenko Ipilimumab plus dacarbazine for previously untreated metastatic melanoma New Engl J Med 364 26 2011 2517 2526
19. A.Y. Bedikian, N. Papadopoulos, C. Plager, O. Eton, and S. Ring Phase II evaluation of temozolomide in metastatic choroidal melanoma Melanoma Res 13 3 2003 303 306
20. R.D. Carvajal, J.A. Sosman, and J.F. Quevedo Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial JAMA 311 23 2014 2397 2405
21. J.J. Sacco, P.D. Nathan, and S. Danson Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma J Clin Oncol 31 suppl. 2013 [abstr 9031]
22. E. D'Angelo, and J. Prat Uterine sarcomas: a review Gynecol Oncol 116 1 2010 131 139
23. F. Ducimetiere, A. Lurkin, and D. Ranchere-Vince Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing PloS One 6 8 2011 e20294
24. P.R. Rosenbaum, and D.B. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1 1983 41 55
25. J. O'Quigley, M. Pepe, and L. Fisher Continual reassessment method: a practical design for phase 1 clinical trials in cancer Biometrics 46 1 1990 33 48
26. D.A. Berry Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis Clin Trials 2 4 2005 295 300 [discussion 1-4, 64-78]
27. O'Hagan A. Bayesian statistics: principles and benefits. In: van Boekel M, Stein A, van Bruggen A, editors. Bayesian statistics and quality modelling in the agro-food production chain; 2004. p. 31-45. [Chapter 3].
28. S.B. Tan, K.B. Dear, P. Bruzzi, and D. Machin Strategy for randomised clinical trials in rare cancers BMJ 327 7405 2003 47 49
29. R.J. Lilford, J.G. Thornton, and D. Braunholtz Clinical trials and rare diseases: a way out of a conundrum BMJ 311 7020 1995 1621 1625
30. K.Y. Bilimoria, D.J. Bentrem, J.D. Wayne, C.Y. Ko, C.L. Bennett, and M.S. Talamonti Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years Ann Surg 249 1 2009 63 71
31. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2008 CA Cancer J Clin 58 2 2008 71 96
32. Forman D, Bray F, Brewster DH, et al., editors. Cancer incidence in five continents, Vol. X (electronic version). Lyon: IARC; 2013.
33. S.B. Tan, Y.F. Chung, B.C. Tai, Y.B. Cheung, and D. Machin Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma Control Clin Trials 24 2 2003 110 121
34. Cancer Research UK. CancerStats 2014, < http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence > [accessed 30.09.14].
35. American Cancer Society. Cancer facts and figures, < http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf >; 2014 [accessed 08.09.14].
36. M.K. Parmar, F.M. Barthel, and M. Sydes Speeding up the evaluation of new agents in cancer J Natl Cancer Inst 100 17 2008 1204 1214
37. P. Royston, M.K.B. Parmar, and W. Qian Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer Stat Med 22 14 2003 2239 2256
38. B. Djulbegovic, A. Kumar, P. Glasziou, B. Miladinovic, and I. Chalmers Medical research: trial unpredictability yields predictable therapy gains Nature 500 7463 2013 395 396
39. M.R. Sydes, M.K.B. Parmar, and N.D. James Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial Trials 10 1 2009 39
40. M.R. Sydes, M.K.B. Parmar, and M.D. Mason Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial Trials 13 1 2012 168
41. M. Paulussen, A.W. Craft, and I. Lewis Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment - cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients J Clin Oncol 26 27 2008 4385 4393